LiPlaCis Phase 2 Recruitment Ongoing in DRP Screened Breast Cancer Patients: Relevant Clinical Benefits in 3 out of 5 Treated Patients
Hoersholm, Denmark, September 19th, 2017 – Oncology Venture Sweden AB (OV:ST) announces early data from the ongoing LiPlaCis® Phase 1/2 study show response and clinical benefits in hard to treat patients with metastatic Breast Cancer. A total of 12-15 patients are to enter the Phase 2 part of the study, which as previously announced is expected to be achieved during this September. So far, a total of eight patients have been included in the phase 2 part, and as of now five of these have received LiPlaCis® treatment during a time period sufficient to evaluate efficacy – please see below!Full